House Dust Mite Allergy Clinical Trial
Official title:
Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02443805 -
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
|
Phase 3 | |
| Completed |
NCT03094845 -
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
|
Phase 2 | |
| Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
| Completed |
NCT01930461 -
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
|
Phase 2 | |
| Completed |
NCT00263549 -
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 4 | |
| Completed |
NCT05019209 -
Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients
|
N/A | |
| Recruiting |
NCT02238353 -
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
|
Phase 4 | |
| Completed |
NCT01454544 -
A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet
|
Phase 3 | |
| Terminated |
NCT01777464 -
Role of the Central Nervous System in Allergic Rhinitis
|
N/A | |
| Completed |
NCT00574223 -
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT02345278 -
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01608243 -
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
|
Phase 1 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT01134757 -
Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.
|
N/A | |
| Recruiting |
NCT05395689 -
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
|
Phase 3 | |
| Not yet recruiting |
NCT05400811 -
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
| Not yet recruiting |
NCT05450289 -
The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy
|
N/A | |
| Recruiting |
NCT05174689 -
Epigenetic Regulation of Exercise Induced Asthma
|
N/A | |
| Terminated |
NCT04874714 -
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT00380926 -
Fish Oil and Asthma in House Dust Mite Allergy
|
Phase 2/Phase 3 |